Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Bayer Ink Deal to Screen Druggable Genes Using RNAi

NEW YORK, Dec. 15 (GenomeWeb News) - Cenix BioScience said today that it has signed a deal to use its genome-wide siRNA library to help Bayer screen all known human druggable genes in an effort to identify and validate new drug targets.


Cenix said that, using cell-based assays developed in partnership with Bayer researchers, it expects to screen more than 6,000 genes in less than nine months.


Under the terms of the deal, Cenix will receive upfront fees and research funding, and is eligible for milestone payments. Bayer will have an option to obtain all rights to new intellectual property generated by the effort.


Additional terms were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.